Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
暂无分享,去创建一个
W. Linehan | R. Srinivasan | W. Rathmell | E. Jonasch | J. Maranchie | S. Welsh | S. Oudard | V. Narayan | O. Iliopoulos | F. Donskov | R. Perini | T. Else | S. Thamake | B. Maughan | E. Park